Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I plus N).

被引：0
|
作者：
Desai, Kunal
Rybicki, Lisa A.
Nizam, Amanda
Wood, Laura S.
Allman, Kimberly D.
Martin, Allison
Calabrese, Cassandra
Gilligan, Timothy D.
Gupta, Shilpa
Ornstein, Moshe Chaim
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17094
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).
    Leong, Sally
    Ali, Sana
    Zengin, Zeynep Busra
    Meza, Luis A.
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Govindarajan, Ameish
    Castro, Daniela V.
    Li, Xiaochen
    Kim, Tane
    Melamed, Sam
    Pal, Sumanta Monty
    Chehrazi-Raffle, Alex
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [32] Ipilimumab and nivolumab (I plus N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.
    Allison, Jennifer
    Griffiths, Richard
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [33] Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab
    Remolina-Bonilla, Yuly A.
    Jimenez-Franco, Brenda
    Lam, Elaine T.
    Bourlon, Maria T.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 171 - 174
  • [34] Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
    Zhou, Shi
    Khanal, Samrat
    Zhang, Haijun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 211 - 221
  • [35] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [36] Healthcare resource utilization (HCRU) and costs for patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line (LOT1) pembrolizumab plus axitinib (P plus A) or ipilimumab plus nivolumab (I plus N).
    Shah, Neil J.
    Shinde, Reshma
    Moore, Kristin
    Sainski-Nguyen, Amy
    Le, Lisa
    Cao, Feng
    Song, Rui
    Singhal, Puneet
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis
    Wang, Shan
    Lv, Hongwei
    Yu, Jing
    Chen, Miao
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 131
  • [38] Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC
    Navani, V.
    Lemelin, A.
    Powles, T. B.
    Liow, E. C. H.
    Wong, S. S. L.
    Meza, L. A.
    Ebrahimi, H.
    Saliby, R. M.
    Saad, E.
    Yuasa, T.
    Wood, L. A.
    Kollmannsberger, C. K.
    Graham, J.
    North, S.
    Basappa, N. S.
    Donskov, F.
    Suarez Rodriguez, C.
    Lalani, A-K.
    Choueiri, T. K.
    Heng, D. Y. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1018 - S1019
  • [39] IMMUNE-RELATED ADVERSE EVENTS (IRAES) MAY INDICATE A FAVORABLE PROGNOSIS IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Evans, Sean
    Goyal, Subir
    Liu, Yuan
    Olsen, T. Anders
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Master, Viraj
    Kucuk, Omer
    Carthon, Bradley
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A380 - A381
  • [40] Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.
    Doshi, Sahil D.
    Lopez Sanmiguel, Andrea
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Shah, Neil J.
    Carlo, Marie
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 540 - 540
12345